Amneal Pharmaceuticals Inc. (AMRX)
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low
COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why
Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?
Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript
Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amneal Pharmaceuticals Q2 Earnings Call Highlights
Amneal Pharmaceuticals NASDAQ: AMRX reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at its AvKARE distribution unit. The company raised its full-year revenue, adjusted EBITDA and adjusted earnings-per-share outlook, citing broad-based demand, new product launches and favorable product mix.
